Pitot, Henry C.

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 7,945

A Dominant Mutation That Predisposes to Multiple Intestinal Neoplasia in the Mouse

Moser, A. R., Pitot, H. C., & Dove, W. F. (1990) · Science

Genetic factors in colorectal cancerCarcinogens and Genotoxicity Assessment

Cited by 1,591

The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04.

Roh, M. S., Yothers, G. A., O'Connell, M. J., Beart, R. W., Pitot, H. C., Shields, A. F., Parda, D. S., Sharif, S., Allegra, C. J., Petrelli, N. J., et al. (2011) · Journal of Clinical Oncology

Colorectal Cancer Surgical TreatmentsColorectal and Anal Carcinomas

Cited by 194

The Aryl Hydrocarbon Receptor Is Required for Developmental Closure of the Ductus Venosus in the Neonatal Mouse

Lahvis, G. P., Pyzalski, R. W., Glover, E., Pitot, H. C., McElwee, M. K., & Bradfield, C. A. (2005) · Molecular Pharmacology

Cardiovascular Conditions and TreatmentsVascular anomalies and interventions

Cited by 168

Liver Tumor Promotion by 2,3,7,8-Tetrachlorodibenzo-p-dioxin Is Dependent on the Aryl Hydrocarbon Receptor and TNF/IL-1 Receptors

Kennedy, G. D., Nukaya, M., Moran, S. M., Glover, E., Weinberg, S., Balbo, S., Hecht, S. S., Pitot, H. C., Drinkwater, N. R., & Bradfield, C. A. (2014) · Toxicological Sciences

Toxic Organic Pollutants ImpactCarcinogens and Genotoxicity Assessment

Cited by 42